January 3, 2019 09:34 AM ESTUpdated May 26, 08:22 PM
R&D
Pharma
Cell/Gene Tx

Take­da builds ar­se­nal for im­muno-on­col­o­gy re­search, cre­ates cell ther­a­py group

Natalie Grover

Reporter

Take­da’s pres­ence in can­cer — for­ti­fied by its $5.2 bil­lion Ari­ad buy­out — is grow­ing, as it an­nounced a range of agree­ments in im­muno-on­col­o­gy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times